CXCR2 and neoplasm: Therefore, inhibiting CXCR2 reduces the pro-tumor effect of neutrophils and enhances the effectiveness of anti-PD-1 immunotherapy by weakening the immune suppression in the tumor microenvironment, boosting T cell activity, and effectively controlling tumor progression [104].